Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6737013 | 0.91 | CYP2A6 (0.37) | CYP2A6CYP1A2TDP1MAPTRXFP1 | |
| SCHEMBL6735637 | 0.90 | CYP2A6 (0.36) | CYP2A6CYP1A2TDP1MAPTKDM4E | |
| SCHEMBL6738004 | 0.88 | CYP2A6 (0.42) | CYP2A6CYP1A2TDP1MAPTRXFP1 | |
| SCHEMBL6731268 | 0.84 | CYP1A2 (0.42) | CYP2A6CYP1A2MAPTALDH1A1HPGD | |
| SCHEMBL6741609 | 0.81 | SKP2 (0.36) | — | |
| SCHEMBL6731904 | 0.80 | TLR8 (0.40) | KDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL21387126 | 0.79 | CYP1A2 (0.39) | CYP2A6CYP1A2TDP1MAPTRXFP1 | |
| SCHEMBL6731332 | 0.78 | TLR8 (0.35) | — | |
| SCHEMBL6736746 | 0.78 | CNR1 (0.37) | CYP2A6CYP1A2MAPTKDM4EALDH1A1 | |
| SCHEMBL6735447 | 0.77 | TLR8 (0.40) | TDP1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6682785-B2 | A FLUOROANTHRACENE COMPOUNDS; HEAT RESISTANCE, RADIATION RESISTANCE, PHOTOSTABILITY | CLARIANT FINANCE (BVI) LIMITED (VG) | 2004-01-27 | — | — | US | disclosed |
| US-20030118749-A1 | A fluoroanthracene compounds; heat resistance, radiation resistance, photostability | CLARIANT INTERNATIONAL LTD. | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118749-A1 | A fluoroanthracene compounds; heat resistance, radiation resistance, photostability | HSF1, ABCC1, FLNA | CYP2A6 1066/4885CYP1A2 80/4885TDP1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.